v3.25.1
Condensed Consolidated Statements of Cash Flows - USD ($)
 9 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Cash flows from operating activities:    
Consolidated net loss $ (13,214,000) $ (17,129,000)
Adjustments to reconcile consolidated net loss to net cash used in operating activities:    
Share-based compensation 1,260,000 1,678,000
Amortization of intangible assets 15,000 15,000
Amortization of finance lease right-of-use assets 203,000 203,000
Amortization of operating lease right-of-use assets 260,000 259,000
Depreciation of fixed assets 363,000 492,000
Gain on sale of fixed assets   (50,000)
Accrued interest receivable on promissory note receivable (47,000) (66,000)
Amortization of deferred financing costs   120,000
Impairment of fixed assets   3,100,000
Gain on sale of intangible assets   (1,000,000)
Accrued payment in kind on term loan   (402,000)
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets (21,000) 318,000
Accounts payable 1,119,000 (621,000)
Accrued expenses (704,000) (496,000)
Operating lease obligations (323,000) (296,000)
Contract liabilities 400,000 175,000
Net cash used in operating activities (10,689,000) (13,700,000)
Cash flows from investing activities:    
Payment received for interest and principal on promissory note receivable 712,000 0
Sale proceeds for intangible assets   1,000,000
Purchase of fixed assets (15,000) 0
Sales proceeds for fixed assets   50,000
Net cash provided by investing activities 697,000 1,050,000
Cash flows from financing activities:    
Proceeds from sales of common stock 1,131,000 11,204,000
Payments for fractional shares after reverse stock split   (7,000)
Proceeds from the exercise of stock options 130,000 0
Subscription receivable   204,000
Payment of equipment financing loan (131,000) (118,000)
Proceeds from term promissory note   895,000
Payment of term promissory note (160,000) (39,000)
Payment of term note payable   (436,000)
Payment of finance lease obligation (221,000) (201,000)
Net cash provided by financing activities 749,000 11,502,000
Net decrease in cash, cash equivalents and restricted cash (9,243,000) (1,148,000)
Cash, cash equivalents and restricted cash - beginning 14,425,000 7,579,000
Cash, cash equivalents and restricted cash - end 5,182,000 6,431,000
Schedule of non-cash activities:    
Indefinite-lived intangible asset addition 750,000  
Shares issued to AstralBio for license fee (750,000)  
Insurance premium financing 697,000 669,000
Subscription receivable   14,104,000
Costs to raise capital paid directly from gross proceeds   1,468,000
Costs to raise capital included in accrued expenses   369,000
Cost accrued to amend term note payable   30,000
Reserves related to term promissory note included in prepaid expenses   109,000
Costs related to tern promissory note paid directly from gross proceeds   68,000
Supplemental cash flow information:    
Cash paid during the period for interest $ 168,000 $ 401,000